The pharmacogenetics of NAT: structural aspects.
Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identifi...
| Prif Awduron: | , , , , |
|---|---|
| Fformat: | Journal article |
| Iaith: | English |
| Cyhoeddwyd: |
2002
|
| _version_ | 1826272582585810944 |
|---|---|
| author | Pompeo, F Brooke, E Kawamura, A Mushtaq, A Sim, E |
| author_facet | Pompeo, F Brooke, E Kawamura, A Mushtaq, A Sim, E |
| author_sort | Pompeo, F |
| collection | OXFORD |
| description | Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme responsible for inactivation of the antitubercular drug isoniazid, an arylhydrazine. The rate of inactivation was polymorphically distributed in the population: the first example of interindividual pharmacogenetic variation. Polymorphism in NAT activity is primarily due to single nucleotide polymorphisms (SNPs) in the coding region of NAT genes. NAT enzymes are widely distributed in eukaryotes and genome sequences have revealed many homologous members of this enzyme family in prokaryotes. The structures of S almonella typhimurium and Mycobacterium smegmatis NATs have been determined, revealing a unique fold in which a catalytic triad (Cys-His-Asp) forms the active site. Determination of prokaryotic and eukaryotic NAT structures could lead to a better understanding of their role in xenobiotics and endogenous metabolism. |
| first_indexed | 2024-03-06T22:14:51Z |
| format | Journal article |
| id | oxford-uuid:53085d2b-8b78-4cb4-99da-53edecf36a4c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:14:51Z |
| publishDate | 2002 |
| record_format | dspace |
| spelling | oxford-uuid:53085d2b-8b78-4cb4-99da-53edecf36a4c2022-03-26T16:29:07ZThe pharmacogenetics of NAT: structural aspects.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:53085d2b-8b78-4cb4-99da-53edecf36a4cEnglishSymplectic Elements at Oxford2002Pompeo, FBrooke, EKawamura, AMushtaq, ASim, EArylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to arylhydrazines and to arylamine drugs and carcinogens or to their N-hydroxylated metabolites. NAT plays an important role in detoxification and metabolic activation of xenobiotics and was first identified as the enzyme responsible for inactivation of the antitubercular drug isoniazid, an arylhydrazine. The rate of inactivation was polymorphically distributed in the population: the first example of interindividual pharmacogenetic variation. Polymorphism in NAT activity is primarily due to single nucleotide polymorphisms (SNPs) in the coding region of NAT genes. NAT enzymes are widely distributed in eukaryotes and genome sequences have revealed many homologous members of this enzyme family in prokaryotes. The structures of S almonella typhimurium and Mycobacterium smegmatis NATs have been determined, revealing a unique fold in which a catalytic triad (Cys-His-Asp) forms the active site. Determination of prokaryotic and eukaryotic NAT structures could lead to a better understanding of their role in xenobiotics and endogenous metabolism. |
| spellingShingle | Pompeo, F Brooke, E Kawamura, A Mushtaq, A Sim, E The pharmacogenetics of NAT: structural aspects. |
| title | The pharmacogenetics of NAT: structural aspects. |
| title_full | The pharmacogenetics of NAT: structural aspects. |
| title_fullStr | The pharmacogenetics of NAT: structural aspects. |
| title_full_unstemmed | The pharmacogenetics of NAT: structural aspects. |
| title_short | The pharmacogenetics of NAT: structural aspects. |
| title_sort | pharmacogenetics of nat structural aspects |
| work_keys_str_mv | AT pompeof thepharmacogeneticsofnatstructuralaspects AT brookee thepharmacogeneticsofnatstructuralaspects AT kawamuraa thepharmacogeneticsofnatstructuralaspects AT mushtaqa thepharmacogeneticsofnatstructuralaspects AT sime thepharmacogeneticsofnatstructuralaspects AT pompeof pharmacogeneticsofnatstructuralaspects AT brookee pharmacogeneticsofnatstructuralaspects AT kawamuraa pharmacogeneticsofnatstructuralaspects AT mushtaqa pharmacogeneticsofnatstructuralaspects AT sime pharmacogeneticsofnatstructuralaspects |